Introduction
Early screening and diagnosis is a key component of tubercu losis control and underpins the post-2015 END TB Strategy aimed at substantially reducing the burden of disease. 1, 2 The Xpert MTB/RIF (Xpert) assay is a rapid molecular-based test that has consistently shown its superior sensitivity over smear microscopy in diagnosing pulmonary, 3 extrapulmonary, 4 and paediatric tuberculosis. 5, 6 As such, it has been endorsed by WHO 7 and is undergoing a large-scale global rollout. 8 However, where Xpert should optimally be placed within national tuberculosis programmes (NTPs) re mains unclear. Should Xpert, to exploit its portability and userfriendly format, be situated in centralised labora tories or within more peripheral clinics at point of care? WHO endorses implementation at centralised health facilities (district and subdistrict levels), but this implementation limits the potential benefits of Xpert as a rapid diagnostic tool. Indeed, later diagnosis and reporting of results, as a consequence of centralised placement, can delay clinical decisions and hence treat ment initiation. 9, 10 Moreover, up to 40% of patients in tuberculosis endemic areas contribute to pretreatment loss to follow-up (ie, they do not return to the clinic to start treatment after being informed of a positive result). [11] [12] [13] A large randomised controlled trial 14 showed that placing Xpert at point of care within primary care clinics was not only feasible, when performed by a minimally trained health-care worker, but significantly reduced pretreatment loss to follow-up. Given these consider ations, a strategic and ideological drive has occurred to move to point-of-care diagnosis-as occurred with HIV, sexually transmitted diseases, and diabetes. Indeed, Xpert is already being used at the point of care in high burden clinics, mines, and prisons in countries such as Zimbabwe and South Africa. Although deployment of Xpert at the point of care can deliver same-day diagnosis [14] [15] [16] and other benefits, as outlined, the associated diagnostic test and clinical infrastructure upgrade costs are not insignificant. 9, 17, 18 Thus, crucial questions for policy makers, and of prime importance to resource allocation planning, are (1) how does the cost of Xpert performed by a minimally trained nurse at point of care compare with when performed by a trained technician at a centralised laboratory; and (2) is point-ofcare placement of Xpert cost-effective? Although multiple studies 17, [19] [20] [21] [22] [23] [24] [25] [26] have examined the economic implications of using Xpert in endemic settings, few have focused on the costs or cost-effectiveness when deployed at point of care, 22, 25, 26 and no studies have calculated cost-effectiveness using clinical outcome data obtained from a pragmatic real-world prospective study. [19] [20] [21] [22] 24, 25 To address these questions, we analysed prospectively collected cost and clinical outcome data from a large randomised control parent trial that recruited patients from primary care clinics in four southern African countries (South Africa, Zambia, Zimbabwe, Tanzania). 14 
Methods

Clinical trial design
We used data obtained from the TB-NEAT trial, 14 which has been described in detail elsewhere. The trial was a random ised, two-group, parallel-group study of 1502 participants with presumptive tuberculosis recruited from periurban primary health-care clinics located in four southern African countries, including South Africa (Cape Town and Durban), Zimbabwe (Harare), Zambia (Lusaka), and Tanzania (Mbeya). Briefly, patients presenting at the clinics with symptoms suggestive of tuberculosis between April 12, 2011, and March 30, 2012, were recruited into the study and randomly assigned to either same-day smear microscopy (n=758; the smear microscopy group) or Xpert MTB/RIF performed at the point of care (n=744; the Xpert group). Specific inclusion and exclusion criteria for patient recruitment can be found in the TB-NEAT paper.
14 Two spot expectorated sputum samples were collected for the index test (smear microscopy or Xpert) and mycobacteria growth indicator tube liquid culture (BD Diagnostics, Sparks, MD USA). Smear microscopy was performed by a qualified technician in a laboratory linked to the clinic. In Cape Town, smear microscopy was done at a centralised laboratory close to the clinic in accordance with South African national diagnostic practices. Auramine fluorescence smear microscopy was instituted at all study sites except Tanzania, which instead used direct light microscopy with Ziehl-Neelsen staining. Xpert was done by a trained nurse (except in Zimbabwe where national policy required Xpert to be performed by a certified technician) using a four-module GeneXpert machine that was situated at each clinic specifically for the trial. An additional Xpert was performed on a stored sputum sample at a centralised laboratory (Lab Xpert) by a qualified technician, and liquid culture was performed at a reference laboratory at each study site. Patients were asked to wait until smear microscopy or Xpert results became available. If results were positive, patients were referred directly to the tuberculosis treatment office in the clinic. Patients with negative results were referred for routine clinical assessment and chest x-ray. Initiation of empirical treatment was decided by the attending clinician. Patients were subsequently followed up for 6 months after diagnosis.
Research in context
Evidence before this study We searched PubMed for all studies published between Jan 1, 2010, and Sept 1, 2018, using the search terms "tuberculosis" OR "(TB)" AND ("cost" OR "cost effectiveness") AND ("Xpert MTB/RIF" OR "GeneXpert"). Many studies investigated the cost-effectiveness of Xpert MTB/RIF (Xpert) for tuberculosis diagnosis in several contexts and settings using modelling approaches. Only one South African study estimated the cost-effectiveness of Xpert in a real-world context with the use of primary economic and clinical data. This study found that Xpert was cost neutral and did not improve the cost-effectiveness of routine tuberculosis diagnosis. However, no published studies assessed the cost-effectiveness of Xpert when performed at the point of care with prospectively collected clinical and cost-related data.
Added value of this study
This study used empirical cost data nested within a randomised controlled trial of point-of-care Xpert versus sputum smear microscopy in four African countries, suggesting that point-of-care Xpert is a cost-effective option for tuberculosis diagnosis in settings willing to pay at least US$3820 per additional patient with tuberculosis completing treatment. The volume of testing in each clinic was the most important determinant of cost and cost-effectiveness of the point-of-care Xpert strategy.
Implications of all the available evidence
Data on the cost-effectiveness of Xpert situated at a centralised laboratory remain discordant. However, the available evidence suggests that, in clinics where volume of testing is sufficiently high to offset implementation costs, point-of-care Xpert testing is likely to provide good value for money in high-burden settings in sub-Saharan Africa.
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Economic evaluation overview
We used clinical and cost data empirically collected from each study site to compare the unit cost of point-of-care Xpert and Lab Xpert at different test volume capacities and to assess the cost-effectiveness of point-of-care Xpert com pared with smear microscopy. We performed the economic analysis according to well established cost-effectiveness analysis guidelines. 27, 28 A completed check list of the essen tial components 27 required for doing an economic analysis is provided in the appendix.
Measures of cost
We calculated tuberculosis diagnosis and treatment costs from the health-care provider perspective in each trial country. We calculated the cost per test for smear microscopy, point-of-care Xpert, Lab Xpert, and chest x-ray. At the time of the study, South Africa was using Xpert for routine tuberculosis diagnosis within the NTP; we measured Lab Xpert costs at the remaining study sites (Zambia, Zimbabwe, and Tanzania) in the respective clinics, but after trial completion (within the context of other ongoing See Online for appendix Costs given in US$, 2014. *X-ray costs in Zimbabwe were taken from the literature 32 because empirical data collection was not possible. †The costs of smear microscopy and Xpert MTB/RIF performed at a centralised laboratory in South Africa were taken as the per-test charge from the National Health Laboratory Services because empirical data collection was not possible. ‡Weighted average of costs across all sites (95%CI), weighted by the number of patients screened at each site. Table 1 : Component and total costs of diagnostic tests and clinic visits in four primary care clinics in southern Africa studies). We also assessed the cost per clinic visit for tuberculosis screening, HIV testing, and counselling and tuberculosis treatment initiation. We estimated the weighted mean (weighted by volume of testing) for the cost per test and cost per clinic visit across all trial sites. We converted local costs to 2014 US$ at exchange rates of $1=R9•65 (South African rand), K5•35 (Zambia kwacha), or TSh1584•05 (Tanzanian shilling) according to Oanda historical exchange rates. At the time of the study, Zimbabwe had already adopted US$ as their national currency. We adjusted costs to the year of ana lysis as necessary using country-specific consumer price indices provided by The World Bank. We annualised capital costs (building, vehicles, and equipment) at a dis count rate of 3%. We estimated expected lifeyears of buildings at 50 years, whereas the expected lifeyears of vehicles and equipment ranged from 3-10 years depending on their frequency of replacement as indicated by staff. Further details on costing methods can be found in the appendix.
Measures of effectiveness
We derived effectiveness measures from clinical outcomes reported in the TB-NEAT trial. 14 We reported outcomes for each individual trial site and subsequently combined for all sites. We only included participants with a valid culture result in the analysis. The measures of effectiveness calculated in each study group (smear microscopy and Xpert) included the number of culturepositive tuberculosis cases: (1) diagnosed by the index test, (2) initiating antituberculosis treatment, (3) initiating antituberculosis treatment on the same day as diagnosis, (4) completing antituberculosis treatment, and (5) having improved morbidity (measured by a numerical tubercu losis score). Completing antituberculosis treatment refers to patients who completed a full 6-month course of antituberculosis treatment and excluded those who were not treatment-adherent, who had died, or who were lost to follow-up (participants started on antituberculosis treatment who were not retained in the study). Improved morbidity refers to patients who started antituberculosis treatment and showed a 25% or more decrease in the well validated tuberculosis score at the end of treatment compared with baseline (see TB-NEAT 14 and Wejse and colleagues 29 for more details on tuberculosis score determination). The TB-NEAT trial was not powered to examine differences in mortality between the two groups. As such, this measure was not included in our analysis. We also reported effectiveness measures 1-5 as a proportion of all individuals clinically suspected of having tuberculosis based on symptom screening. Out comes were normalised to 1000 people with suspected tuberculosis screened in each study group. Incremental effectiveness (per 1000 people with suspected tuberculosis screened) was also reported. We used incre mental costs and outcomes to calculate the incremental cost-effectiveness ratio (ICER) for selected outcomes among culture-positive cases. Further details regarding assumptions used in the analysis can be found in the appendix.
Sensitivity analysis
We did univariate sensitivity analyses to calculate the effect of varying specific parameter inputs on the cost per test of point-of-care Xpert and the incremental cost per culture-positive patient starting treatment. We also did a probabilistic sensitivity analysis to calculate the uncertainty around ICERs given the challenges in estimating their confidence intervals. 30 This analysis involves simultaneously varying cost and effectiveness parameter inputs with the use of 10 000 randomly sampled estimates drawn from their defined probability distributions. We confirmed that 10 000 simulations would be sufficient for model convergence around the uncertainty using a previously published approach. 31 Briefly, we generated ICERs for each outcome using two separate sets of 10 000 randomly sampled estimates to ensure that the mean values of each set of simulations fell within the 95% CI range of the corresponding set (appendix). We also doubled the number of simulations from 10 000 to 20 000 to confirm the width of the 95% CIs were effectively unchanged (appendix). We calcu lated ICERs for each estimate and used them to construct a cost-effectiveness acceptability curve to establish the probability that point-of-care Xpert would be considered cost-effective compared with smear microscopy over a range of willingness-to-pay thresholds. Statistical analysis was done using GraphPad Prism version 6.0 and Microsoft Excel 2016.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or the writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
The cost per Xpert assay performed at the clinic (ie, point-of-care Xpert) and at a centralised laboratory (ie, Lab Xpert) was calculated at each study site to allow for cost com parisons at different levels of programmatic implemen tation. Component costs included con sumables, staff, equip ment, overheads, quality control, and transport. Under . Under observed conditions, Lab Xpert test volumes were 2-5 times higher than the point-of-care Xpert at any given testing facility. Point-of-care Xpert became less costly than Lab Xpert under the assumption that annual test volume estimates were equiva lent (figure 1; appendix). Unit test and clinic costs, including the cost breakdown, are reported in table 1. Figure 2A and 2B (appendix) show differences in clinical outcomes comparing point-of-care Xpert to smear mi croscopy, both among culture-positive patients and symp tom atic patients. For example, when comparing point-of-care Xpert to smear microscopy, the difference in culture-confirmed tuberculosis cases starting antituberculosis treatment was 24•3 cases per 1000 people screened (95% CI -20·0 to 68·5) and in those completing antituberculosis treatment was 29•4 cases per 1000 people screened (-6·9 to 65·6). In terms of incremental costs, point-of-care Xpert was more expensive than smear microscopy, with costs ranging from $28 503 per 1000 people screened in Zimbabwe to $53 280 in Tanzania. Across all study sites, the incremental cost amounted to $35 528 per 1000 people screened (27 053-40 024) and was strongly associated with the unit cost of point-of-care Xpert ( figure 2C) .
The cost-effectiveness of point-of-care Xpert for the individual and combined study sites is reported as the incre mental cost per selected outcome among culture positive tuberculosis cases (table 2) . Cost-effectiveness estimates varied widely across study sites, with cost per treatment initiation ranging from $984 in South Africa to $2699 in Zambia (weighted mean of $1464 per treatment initiation) and cost per treatment completion ranging from $465 per treatment completed in Zambia to $8485 in South Africa (weighted mean $1211 per treatment completed). We also compared our cost-effectiveness estimates to other estimates of tuberculosis inter ventional strategies, in terms of disability-adjusted life-years (DALYs) averted, from the published literature (appendix). 24, 33, 34 In this comparison, our baseline cost-effectiveness estimates, in most cases, decreased to less than 3 times the gross domestic product (GDP) per capita per DALY averted in each country.
In one-way sensitivity analysis, the expected useful life, purchase price, and annual test volume of the Gene Xpert machine had the greatest influence on the point-of-care Xpert unit cost ( figure 3A) . A similar pattern was ob served on the incremental cost per treatment initiation and treatment completion among culture-positive patients. However, the largest influence on cost per treat ment initiation was the proportion of culture-positive patients starting treatment. In the point-of-care Xpert group of the trial, Costs are in $US, 2014. *Weighted average of costs and outcomes across all sites, weighted by the number of patients screened and number of clinical outcomes observed at each site. †Indicates that point-of-care Xpert was both more expensive and less effective than smear microscopy for that particular clinical outcome. figure 3B) . Similarly, reducing the proportion of culture-positive patients completing treatment from 60% to 50% increased the estimated cost per treatment completion from $1211 to $3445. A similar pattern was also observed if the number of patients who were lost to follow-up was varied ( figure 3C ). Figure 4 shows the willingness-to-pay thresholds at which point-of-care Xpert would be preferred over smear mi croscopy across 10 000 probabilistic simulations. Assuming that a 90% probability of cost-effectiveness might make an effective decision threshold, point-of-care Xpert would be preferred at this threshold in settings willing to pay $9450 per culture positive patient diagnosed, $4450 per patient starting treatment, $1600 per patient starting treatment on the same day as diagnosis, $3820 per patient completing treatment, or $5840 per patient with improved morbidity. Willingness-to-pay thresholds at other cost-effectiveness probability estimates are shown in the appendix.
Discussion
The primary findings of this economic evaluation, nested within a clinical trial across four Southern African coun tries, is that point-of-care Xpert, while more costly than smear microscopy, is likely to be cost-effective (in >90% of simulations) in settings willing to pay at least $4500 per treatment initiation or $3800 per treatment completion among culture-positive patients. High test volume capacity at primary care clinics is probably necessary for Xpert point-of-care placement to be economically feasible in many settings.
Few studies have estimated the economic effect of implementing Xpert at the point of care 22, 25, 26 and all have used modelling analyses rather than prospectively obtained trial data to assess cost-effectiveness. 19, 20, 24, 25, 35 In most of these modelling studies, Xpert was cost-effective either as a full replacement 19, 24, 25, 35 or in conjunction with other diagnostic tests 20, 21 compared with the standard of care (smearmicroscopy). However, some of these studies did not incorporate empirical treatment and thus might have overestimated the effectiveness of Xpert. 24, 25 Our estimates of cost-effectiveness account for levels of empirical treatment observed in the TB-NEAT trial and require fewer modelling assumptions than these previous analyses but might, there fore, underestimate the effectiveness of point-of-care Xpert by not explicitly accounting for effects on secondary transmission. Conversely, clinical trials can provide direct and real-world data on patient important outcomes related to Xpert implementation. For example, the XTEND trial 15 assessed the effect of Xpert relative to smear microscopy on patient morbidity and mortality when placed at central laboratories within the context of the South Africa national Xpert rollout. Similar to TB-NEAT, no significant differences were observed in terms of patient morbidity or mortality. A subsequent follow-up cost-effectiveness analysis showed that the South African Xpert rollout was cost neutral and failed to improve the cost-effectiveness of tubercu losis diagnosis, probably due to the trial finding no benefits to mortality. 23 Conversely, in our study we used clin ical endpoints from the TB-NEAT trial rather than mortality or health utility (eg, DALYs as more direct measures of effectiveness). We estimated that, relative to smear microscopy, point-of-care Xpert is likely to cost $1464 per treatment initiation and $1211 per treatment completion among patients with culture-confirmed tubercu losis.
In deciding whether point-of-care Xpert would be cost-effective, there is no consensus on appropriate Figure 4 : Cost-effectiveness acceptability curves for selected incremental cost-effectiveness ratios The probability of point-of-care Xpert, relative to smear microscopy, being cost-effective was plotted as a function of willingness to pay per culture-positive patient diagnosed by the index test (A), starting treatment (B), starting treatment on same day as diagnosis (C), completing treatment (D), and experiencing improved morbidity for all sites combined (E). The arrow indicates the willingness-to-pay threshold, at which the probability of cost-effectiveness is 90%. Xpert=Xpert MTB/RIF. willingness-to-pay thresholds, and the use of generic thresholds have been largely criticised. [36] [37] [38] Cost-effectiveness thresholds provide no information on affordability and do not have the disease-specific context in which scale-up of point-of-care Xpert could have major implications on resource allocation within the NTP. Nonetheless, a commonly used metric for highly costeffective interventions is the per-capita GDP (or gross national income) per DALY averted (or 3 times this value for cost-effective interventions). To keep our analysis faithful to trial-measured outcomes (with a minimum of modelling assumptions), we did not measure outcomes in terms of DALYs averted. However, we did compare our results to those of other model-based economic evaluations from which a ratio could be calcu lated of clinical outcomes (as calculated in this study) to DALYs averted (appendix). 24, 33, 34 Our estimates in these com parisons were substantially less favourable toward point-of-care Xpert (eg, incremental cost-effectiveness ratio 10 times higher than reported by Vassall and col leagues), 24 probably because our estimates incorporate the levels of empirical treatment observed in the TB-NEAT trial. Nevertheless, our estimates of point-of-care Xpert cost-effectiveness in most cases come below a threshold of 3 times per-capita GDP per DALY averted, suggesting cost-effectiveness of this intervention according to this classical willingness-topay threshold. These results do not speak to the affordability of point-of-care Xpert under existing budget constraints, but they do suggest that the cost-effectiveness of point-of-care Xpert is likely to be at least equivalent to that of many other interventions that have been characterised as cost-effective in the scientific literature up to now.
Another useful metric to assess cost-effectiveness and willingness to pay is the potential health gains if provided with a fixed monetary sum. For example, if an additional $10 000 was provided to the NTP for the Xpert point-of-care strategy, the expected gains over smear microscopy would be an additional four tuberculosis cases diagnosed, 12 cases starting treatment, 30 cases starting same-day treatment, and 14 cases completing treatment (appendix). Thus, policy makers can directly compare these values to other tuberculosis diagnostic strategies to assess the relative expected value of investment in point-of-care Xpert.
The TB-NEAT trial showed an increase in the number of Xpert-positive culture-negative individuals that were placed on treatment. Conversely, a Brazilian study 35 showed a reduction in these Xpert false positives (with culture as a gold standard) compared with smear microscopy. Such discrepancies between Xpert and culture could represent false-negative culture results but might also reflect false-positive Xpert results due to residual Mycobacterium tuberculosis DNA, particularly in people previously (and successfully) treated for tuberculosis. 39 If some of these individuals who start treatment do indeed represent Xpert false-positives, it will be important to establish the extent of such Xpert-based overtreatment in various settings because the cost of such overtreatment ($113 per patient in our analysis) is not inconsequential.
The TB-NEAT study also showed much higher smear microscopy-based empirical treatment decisions compared with Xpert and probably explains why no incremental morbidity benefit was observed in the trial. To the extent that such empirical diagnoses represent people without underlying tuberculosis, the true cost-effectiveness of point-of-care Xpert might be even more favourable than reported here.
This study also speaks to the cost implications of placing Xpert at the point of care versus a centralised facility. In our analysis, test capacity was a major influence driving the unit cost of Xpert. However, despite annual test volumes being 2-5 times higher when Xpert was positioned in the laboratory, point-of-care Xpert was only slightly more expensive on a per-test basis in some settings due to reductions in sample transport and overhead costs (table 1) . Additionally, the variation in Lab Xpert test costs across study settings reflects the different laboratory setups at each site. For example, more GeneXpert machines were in use at the centralised laboratory in Zambia accounting for the higher Lab Xpert costs at that site.
In most countries, Xpert has been positioned at subdistrict level laboratories within the NTP rather than at the peripheral level, probably due to the financial and logistical limitations of point-of-care placement. A 2011 South African study 17 projected that national implementation of Xpert at the point of care would cost 51% more than lab placement, equivalent to an estimated $36 million per year. This cost represents a major hurdle to point-ofcare placement, especially in other high burden countries where NTP budgets are under severe financial constraints. 40 However, these costs should be interpreted with in the overall context of the economic effect of tubercu losis; one report 41 estimated that, over the next 15 years, economic losses due to tuberculosis would amount to about $300 billion in the African region (equating to about 2-3% of the GDP in the case of some African countries, including South Africa) and close to $1 trillion globally. The cost implications on patients can also be substantial, especially in low-income countries where tuberculosis disease can consume close to 60% of an individual's income. 42 Additional concerns of point-ofcare placement include the need for a stable electricity supply, temperature control, and adequate storage facilities. 9, 18 However, placement of Xpert at centralised facilities diminishes its potential to improve patient outcomes. 9 One potential solution might involve targeting point-of-care Xpert placement at specific primary care facilities where cost and health benefits can be maximised. For example, point-of-care implementation of Xpert might first be prioritised to clinics (1) in tuberculosis hotspots-ie, periurban slums where the disease burden is high, (2) where transportation of samples to central labora tory facilities is difficult and delays in result reporting are common, (3) where empirical treatment initi ation is uncommon, and (4) where the incidence of drug resistance and rates of loss to follow up are high. Any implementation strategy will need to be assessed in the context of newer Xpert technologies, such as the more point-of-care-friendly Xpert Edge instrument (recently released and uses the more sensitive Xpert Ultra cartridge), 43 and point-of-care molecular platforms in development (eg, QuantuMDx. etc). 44 Our study had several limitations. First, we did not account for rifampicin (RIF) resistance detection, a major advantage of Xpert, in our analysis. The parent trial was not powered for detection of drug resistance, and the additional effectiveness gained by RIF resistance detection is not directly comparable to smear microscopy without incorporating another method of drug resistance testing, such as line probe assay, which was not performed in the study. Incorporation of RIF resistance detection might make Xpert more cost-effective by reducing the time to treatment in positive cases but might also favour smear microscopy because of the possibility for false-positive diagnosis of RIF resistance by Xpert. Second, our results are difficult to directly compare with those that used single utility metrics, such as DALYs. However, we chose to compare costs using hard data and real-world clinical outcomes (obtained from several settings) rather than to estimate a measure (eg, DALYs), which requires extensive assumptions about the downstream consequences of a diverse array of clinical outcomes based on sparse data. We also did not attempt to estimate effects on secondary transmission for similar reasons; thus, our findings, like for resistance detection, might be biased against point-of-care Xpert, which significantly shortened time to diagnosis in the trial. Third, economic evaluation within the context of a clinical trial has inherent limitations. Although able to provide direct data in specific settings compared with modelling, resource use and patient recruitment is often restricted to the selection criteria of the trial protocol. 45 However, TB-NEAT was designed with pragmatic implemen tation in mind, which might mitigate this concern to some degree, and empirical cost data was collected in a standardised way from multiple highburden settings, which might not have been possible outside the context of a clinical trial. The cost of Lab Xpert used in our analysis (figure 1) was taken from the National Health Laboratory Service (NHLS) in South Africa but might be lower than if estimated with the use of empirically collected cost data. 46 The NHLS Lab Xpert cost estimate was chosen because it represents the cost charged to the South African government and thus represents the actual cost incurred from the health-care provider perspective. Several other studies [47] [48] [49] have used this estimate for similar reasons. Finally, some limitations were also related to measurement uncertainty of costs and outcomes. The large differences in incremental cost-effectiveness observed between the different study sites was primarily driven by differences in effective ness measures. However, these differences should be interpreted with caution because of the low recruit ment number at any given site (eg, wide 95% CIs were reported for patient outcomes in Tanzania) and that the TB-NEAT clinical trial was not powered to detect differences across the various study site.
In summary, we have estimated the cost-effectiveness of implementing Xpert at the point of care in four different African settings. Overall, our results indicate that a point-of-care-based Xpert can offer good value for money relative to other tuberculosis diagnostic strategies, though the cost-effectiveness of this strategy is likely to be even higher given that transmission reduction and drug resistance detection were not factored into the analysis. These findings will facilitate decision making about public health strategy and resource allocation by NTPs so that cost savings and health benefits can be maximised.
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